The preventable burden of pneumococcal disease in the developing world

Area of Science:

• * Global Health
• * Vaccinology
• * Infectious Disease Epidemiology

Background:

• * Pneumococcal conjugate vaccines (PCV) have demonstrated high efficacy in North America.
• * Defining the burden of pneumococcal disease is crucial for assessing PCV benefits in developing countries.
• * Existing data highlight a significant burden of pneumococcal disease in low-resource settings.

Purpose of the Study:

• * To estimate the burden of pneumococcal disease in developing countries.
• * To assess the potential benefits and impact of pneumococcal conjugate vaccines (PCV) in these regions.
• * To identify factors influencing PCV effectiveness, including herd protection and serotype replacement.

Main Methods:

• * Analysis of community-based incidence studies of invasive pneumococcal disease (IPD).
• * Review of vaccine probe analyses from efficacy trials.
• * Epidemiological assessment of pneumococcal disease burden and serotype distribution.

Main Results:

• * An estimated 814,000 deaths in children under 5 years occur annually in developing countries due to pneumococcal disease.
• * Africa alone experiences 1-4 million episodes of pneumococcal pneumonia each year.
• * The burden of IPD attributable to vaccine serotypes is a key factor for PCV effectiveness.

Conclusions:

• * Pneumococcal conjugate vaccines (PCV) are likely to be effective in settings with a high burden of IPD caused by vaccine serotypes.
• * Herd protection and serotype replacement effects remain unpredictable due to limited epidemiological data in developing countries.
• * Operational deployment and monitoring of PCV in well-resourced settings are essential for accurate impact assessment.